| Bioactivity | Mipsagargin (G-202) is a novel thapsigargin-based targeted prodrug consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research[1][2][3]. |
| Invitro | Mipsagargin (G-202) 作用于不产生 PSMA 的 TSU 细胞 (IC50=191 nM)，是产生 PSMA 的 LNCaP 细胞的 57 倍 (IC50=5351 nM)[2]。 |
| Name | Mipsagargin |
| CAS | 1245732-48-2 |
| Sequence | Asp-{Ggu}-{Ggu}-{Ggu}-{Ggu} |
| Shortening | D{Ggu}-{Ggu}-{Ggu}-{Ggu} |
| Formula | C66H100N6O27 |
| Molar Mass | 1409.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Mipsagargin
CAS: 1245732-48-2 F: C66H100N6O27 W: 1409.52
Mipsagargin (G-202) is a novel thapsigargin-based targeted prodrug consisting of a prostate-specific membrane antigen (P
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.